Yes. Several clinical studies have shown that HITHOC can extend survival in pleural mesothelioma patients.
For example, a 2023 review of the National Cancer Database revealed that patients who underwent HITHOC after surgery had a median life expectancy of 20.5 months, compared to 16.8 months for patients treated with surgery alone.